Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972908 | 0.72 | KMT2A (0.44) | KDM4EKMT2AADORA2AALDH1A1RXFP1 | |
| SCHEMBL1689509 | 0.72 | KDM4E (0.47) | KDM4EKMT2AADORA2AALDH1A1ADORA2B | |
| SCHEMBL14972716 | 0.71 | KDM4E (0.36) | KDM4EKMT2AADORA2AALDH1A1RXFP1 | |
| SCHEMBL9972905 | 0.69 | TRPA1 (0.32) | KDM4EADORA2AADORA2B | |
| SCHEMBL15472439 | 0.68 | ADORA2A (0.43) | KDM4EKMT2AADORA2ARXFP1ADORA2B | |
| SCHEMBL1689535 | 0.68 | ADORA2B (0.40) | KDM4EKMT2AADORA2AALDH1A1RXFP1 | |
| SCHEMBL3716133 | 0.68 | ADORA2B (0.38) | KDM4EKMT2AADORA2AALDH1A1RXFP1 | |
| SCHEMBL9972894 | 0.68 | KDM4E (0.58) | KDM4EALDH1A1LMNAJAK2HPGD | |
| SCHEMBL13190508 | 0.67 | ALOX15 (0.42) | KDM4EALDH1A1ADORA2BLMNAHPGD | |
| SCHEMBL9972876 | 0.66 | KDM4E (0.37) | KDM4EKMT2AADORA2AALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073955-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-8889862-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | KDM4E 4035/4885KMT2A 2406/4885ADORA2A 81/4885 |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | KDM4E 4154/4885KMT2A 2625/4885ADORA2A 63/4885 |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | KDM4E 4154/4885KMT2A 2625/4885ADORA2A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.